Dexcom said preliminary, unaudited total revenue for Q4 2024 was at least $1.113 billion, an increase of 8% over Q4 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4%, and international revenue is expected to be approximately $310 million, an increase of 17%.

1. 01

   Dexcom said preliminary, unaudited total revenue for Q4 2024 was at least $1.113 billion, an increase of 8% over Q4 2023. U.S. revenue is expected to be approximately $803 million, representing growth of 4%, and international revenue is expected to be approximately $310 million, an increase of 17%.

2. 02

   For 2024, Dexcom reported preliminary, unaudited total revenue of approximately $4.032 billion, an increase of 11% over 2023. The company said it is updating 2024 Non-GAAP Gross Profit Margin and Non-GAAP Operating Margin guidance to 62% and 19% respectively.

3. 03

   Dexcom said fourth quarter gross margin is expected to be adversely impacted by a non-cash charge. The company explained the charge is primarily related to inventory damaged in transit and certain build configurations that lowered production yield for Q4.

4. 04

   For 2025, Dexcom currently anticipates total revenue of $4.60 billion, representing expected growth of approximately 14% over 2024. The company estimates 2025 Non-GAAP Gross Profit Margin to be approximately 64 to 65% and Non-GAAP Operating Margin to be approximately 21%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.